LEVI-04

Levicept's LEVI-04, a non-opioid drug, significantly reduced pain in patients with moderate-to-severe osteoarthritis of the knee in a Phase 2 trial.

Levicept's LEVI-04 met its primary endpoint in a Phase II trial, showing significant pain reduction in osteoarthritis patients across all doses.

Levicept's LEVI-04 met its primary endpoint in a Phase II trial, demonstrating significant pain reduction in patients with moderate to severe osteoarthritis.

Levicept's LEVI-04, a novel p75NTR-Fc fusion protein, demonstrated substantial improvements in pain and function in patients with knee osteoarthritis in a Phase II trial.

Levicept's LEVI-04, a novel p75NTR-Fc fusion protein, shows substantial improvements in pain and function for knee osteoarthritis patients in Phase II trial.